Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the
Myelodysplastic Syndromes (MDS)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
BACKGROUND:
Guadecitabine is a next-generation hypomethylating agent whose active metabolite decitabine decitabine: It works by reducing the amount of methylation in the body.
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet. Recently, absence of response has been associated with increased cell-cycle quiescence among the hematopoietic progenitor cells.
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
This PDQ cancer information summary has current information about the treatment of myelodysplastic syndromes myelodysplastic syndromes:
Getting personal with myelodysplastic syndromes: is now the right time?
Commonly used scoring systems rely on blood counts, histological and cytological examination of bone marrow bone marrow: The soft, spongy tissue inside most bones.
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Immunosuppressive therapy Immunosuppressive therapy: Immunosuppressive drug therapy lowers your body's immune response.
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
Myeloid neoplasms, including myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A grou
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge
A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow biopsy bone marrow biopsy: A medical procedur